FENopta – Talk Bio

Actionable Insights Powered by AI

Roche’s Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Phase II Trial

Roche, fenebrutinib, relapsing multiple sclerosis, BTK inhibitor, Phase II trial, FENopta study